CD177, MYBL2, and RRM2 Are Potential Biomarkers for Musculoskeletal Infections.

Area of Science:

• Biomarker discovery in infectious diseases.
• Molecular diagnostics for musculoskeletal infections.
• Translational research in infection detection.

Background:

• Biomarkers are crucial for infection detection and treatment monitoring.
• Previous studies identified CD177, MYBL2, and RRM2 in diabetic foot infections.
• This study investigates their potential in broader musculoskeletal infections.

Purpose of the Study:

• To determine if CD177, MYBL2, and RRM2 protein concentrations are elevated in patients with musculoskeletal infections.
• To assess if these biomarker levels decrease with antibiotic treatment.
• To evaluate the diagnostic accuracy of these biomarkers for musculoskeletal infections.

Main Methods:

• Blood samples were collected from 19 patients with musculoskeletal infections and 21 controls.
• Serum and PBMC protein concentrations of CD177, MYBL2, and RRM2 were measured.
• qRT-PCR and ELISA were used for quantification.
• Diagnostic accuracy was assessed using ROC curve analysis.

Main Results:

• Significantly higher serum and PBMC concentrations of CD177, MYBL2, and RRM2 were observed in the infection group compared to controls.
• Biomarker levels decreased significantly after antibiotic therapy in treated patients.
• ROC analysis indicated high diagnostic accuracy for these biomarkers (AUC > 0.96 for all).

Conclusions:

• CD177, MYBL2, and RRM2 show promise as blood-based biomarkers for diagnosing musculoskeletal infections.
• These biomarkers may also aid in monitoring treatment response.
• Further large-scale studies are needed to confirm their utility in differentiating infections from other inflammatory conditions.